Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001
- PMID: 12843750
- DOI: 10.1097/00126334-200307010-00013
Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001
Abstract
In naive HIV-1 infected patients who start a highly active antiretroviral therapy (HAART), the relationship between time-updated CD4+ cell count, HIV RNA, and clinical progression (new AIDS-defining event or death) is incompletely understood. A 2-step statistical approach was adopted: first, modeling the evolution of the 2 markers taking into account left-censoring of HIV RNA and, second, studying their respective effect on clinical progression. The study sample consisted in 551 previously untreated patients of the Aquitaine Cohort who started their first HAART regimen between 1996 and 2000. During a median follow-up of 33 months, 46 patients experienced a new AIDS-defining diagnosis and 23 died. In multivariate survival analysis, time-updated CD4+ cell count (hazard ratio [HR] = 1.92 for 100 cells/mm3 lower, P < 10(-4) and HIV RNA (HR = 1.30 for 1 log(10) copies/mL higher, P = 0.04) on continuous scale were associated with clinical progression. When analyzing the effect of updated biomarkers using usual thresholds, the association with clinical progression was weaker for CD4+ but still significant (P = 0.007) whereas it remained only significant for updated HIV RNA above 4 log(10) copies/mL (P = 0.01). The prognostic information of updated HIV RNA adjusted on updated CD4+ is significant but depends on how the markers are taken into account. Clinical decisions and interpretation of clinical trial results must weigh the signification of each of these 2 biomarkers.
Similar articles
-
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.AIDS. 2001 Nov 23;15(17):2251-7. doi: 10.1097/00002030-200111230-00006. AIDS. 2001. PMID: 11698698
-
Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.HIV Clin Trials. 2005 May-Jun;6(3):127-35. doi: 10.1310/A9B9-RQD7-U8KA-503U. HIV Clin Trials. 2005. PMID: 16192247 Clinical Trial.
-
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.J Infect Dis. 2007 Feb 1;195(3):425-31. doi: 10.1086/510536. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205482
-
Model of HIV-1 disease progression based on virus-induced lymph node homing and homing-induced apoptosis of CD4+ lymphocytes.J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):352-62. doi: 10.1097/00126334-200008010-00010. J Acquir Immune Defic Syndr. 2000. PMID: 11015152 Review.
-
CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.J Transl Med. 2011 Jun 16;9:93. doi: 10.1186/1479-5876-9-93. J Transl Med. 2011. PMID: 21679413 Free PMC article. Review.
Cited by
-
Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.Clin Pharmacokinet. 2005;44(6):591-625. doi: 10.2165/00003088-200544060-00003. Clin Pharmacokinet. 2005. PMID: 15910009 Review.
-
Variability of Prognostic Results Based on Biological Parameters in Sickle Cell Disease Cohort Studies in Children: What Should Clinicians Know?Children (Basel). 2021 Feb 13;8(2):143. doi: 10.3390/children8020143. Children (Basel). 2021. PMID: 33668629 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials